Dr. Maria Maccecchini is the Founder, President, and CEO of Annovis Bio, which she established in 2008 to develop therapies for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.

‍

She is a biochemist and entrepreneur with over 30 years of experience in neurodegeneration research and drug development. She previously founded Symphony Pharmaceuticals (acquired by Transgenomic in 2001) and has held senior roles including General Manager of Bachem Bioscience (U.S.) and Head of Molecular Biology at Mallinckrodt. She has also served as Partner and Director at Robin Hood Ventures and MidAtlantic Angel Group.

‍

Dr. Maccecchini completed postdoctoral training at Caltech and the Roche Institute of Immunology, earned her Ph.D. in Biochemistry from the Biozentrum of the University of Basel, and was a visiting fellow at The Rockefeller University.

‍

In 2009, she founded Annovis Bio (formerly QR Pharma) following the in-licensing of buntanetap from the U.S. National Institute on Aging. Originally developed for Alzheimer’s disease, buntanetap was later shown to reduce multiple neurotoxic proteins through a shared translational mechanism, enabling Annovis to expand its focus to neurodegeneration more broadly, including Parkinson’s disease.

‍

Mr. Guerin is a financial executive and leader with demonstrated expertise leading accounting, finance, human resources and IT activities in publicly-traded and venture-backed companies. He effectively directed, managed, and performed a full scope of finance functions including public offerings, rights offering, registered direct offerings, and more.

Most recently, he worked as CFO at Onconova Therapeutics, now known as Traws Pharma, Inc. (Nasdaq: TRAW), where he supported several critical financing transactions, including a rights offering, public offerings, registered direct offerings, and at-the-market offerings. Prior, he served as Vice President of Finance and CFO at Cardiokine, Inc. and as Director, Financial Reporting and Internal Controls at Barrier Therapeutics, Inc.

‍

Dr. Fang oversees the design and execution of Annovis' clinical programs and leads the Company’s interactions with regulatory agencies to ensure rigorous and compliant trial conduct. Most recently, she designed and oversaw the implementation of the Phase 2/3 AD and the Phase 3 PD studies, including data analysis across both programs.

‍

Dr. Fang has dedicated her career to understanding and treating neurodegenerative diseases, including Alzheimer’s, prion, and Huntington’s diseases. She brings deep scientific expertise across translational research, clinical development, and regulatory strategy, with a strong focus on advancing therapies from bench to bedside. She earned her Ph.D. in Neuroscience from The Pennsylvania State University and her Bachelor’s degree in Biopharmaceutical Sciences from Nanjing University.

‍

Dr. Fang held senior leadership and academic roles, including:

• Senior VP, Research & Development, Annovis
• VP of Research, Annovis; Scientific Consultant, Clarivate
• Research Faculty, Boston University
• Postdoctoral Fellow, Oregon Health & Science University (OHSU)
• Graduate Trainee, The Pennsylvania State University.

‍

Throughout her career, Dr. Fang has received numerous honors recognizing her scientific and leadership contributions, including:

• The Medicine Maker Power List (2022)
• Executive Committee Member, Philadelphia Science History Museum
• Fellowship Awardee, National Multiple Sclerosis Society (2010–2012)
• First Prize, Poster Presentation — Prion Annual Meeting (2015)
• Best Postdoctoral Talk — Society for Neuroscience (2012)
• Best Talk — National Multiple Sclerosis Society Tykeson Fellow Meeting (2011)
• Tartar Fellowship, Oregon Health & Science University (2008)
• Braddock Graduate Fellowship, The Pennsylvania State University (2005)

‍

Dr. Christie has spent over 40 years in the pharmaceutical industry, with a focus on process chemistry R&D, pilot plant production and GMP operations. He has held senior management positions in both large (SmithKline, Rhodia, Teva) and mid-size (Cephalon) companies, as well as being the founder of a company providing contract process R&D services (later acquired by ChiRex). His recent achievements at Annovis include:

• Leading the discovery of a new crystal form of buntanetap
• Supervising development of the manufacturing process of crystal form of buntanetap
• Co-authoring two patents for Form B and its manufacturing process

‍

Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.

‍

Ms. Gaines is an accomplished clinical research professional with over 20 years’ experience garnered from positions held in academia, contract research organizations and pharmaceutical companies. She has proven abilities in monitoring and management of Phase I to Phase IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and many psychiatric diseases in both adult and pediatric populations.

‍

Ms. Gaines has demonstrated proven success in leading cross-functional teams as well as driving operational success. In her current role as VP, Clinical Operations she oversees and supports all clinical project activities. Melissa Gaines received here B.A. in Psychology form Millersville University of Pennsylvania.

‍

Throughout her career, she has held multiple positions including:

• Vice President and Senior Vice President of Clinical Operations at Annovis Bio
• Senior Director of Clinical Operations and Site Management at Worldwide Clinical Trials
• Director of Clinical Operations at INC Research
• Clinical Scientist in the Neuroscience Division at Wyeth Research
• Research Manager at Research Pharmaceutical Services
• Clinical Research Coordinator at George Washington University
• Research Associate and Manager at the University of Maryland
• Counselor and Case Manager at Community Services Group

Ms. Damiano has spent over 40 years in the biotechnology sector, focusing on the definition and execution of regulatory strategies and GxP compliance, encompassing early phase development through commercialization. At Annovis, her focus has been on regulatory and operational planning, including preparing submissions to the FDA, and overseeing contracted organizations for manufacturing, preclinical, and early phase clinical projects. Specifically, she accomplished the following:

• Managed vendors for on-time delivery of GMP clinical trial supplies for all studies
• Facilitated key meetings with FDA to define pivotal milestones in buntanetap development
• Ensured completion of nonclinical safety studies required to progress the buntanetap development program

‍

Ms. Damiano holds an accomplished track record in the definition and execution of regulatory strategies, including the development of innovative solutions and effective management of projects and resources to meet company objectives. She has held various senior management positions throughout her career, with experience garnered at companies including Centocor, MedImmune, OraSure Technologies and Vicuron Pharmaceuticals. Ms. Damiano is Regulatory Affairs Certified, holds a Master of Science degree and is currently pursuing her Doctorate in Health Sciences.

‍

Sarah MacCallum joined Annovis Bio as Senior Clinical Project Manager in 2023. She was promoted to Director of Clinical Operations in 2024, and currently supports all clinical trial activities. She is an experienced Clinical Project Manager and Registered Nurse, who has spent over a decade building skills in clinical research on a foundation of direct patient care. Her achievements include:

• Exceeded targeted enrollment for the Phase II/III AD study in record time
• Ensured data integrity by leading site audits for regulatory compliance
• Supported patients and families by connecting them with clinical trial sites and trial information

‍

Her clinical trial background includes neuro-oncology, breast and bowel cancer, cardiology, pediatric organ transplant, and neuromuscular disorders. She has worked at the site, CRO, and sponsor levels in various roles before joining the Annovis Bio team as Senior Clinical Project Manager for Clinical Operations. Sarah received her Bachelor of Science in Nursing from Saint Louis University and a Bachelor of Arts in English from The Ohio State University.

‍

Dr. Morin is an expert in scientific communications who is passionate about translating complex science into digestible information. He comes from an academic background where he spent several years working on drug discovery projects for traumatic brain injuries. Later, he worked in a CRO helping design studies for different indications. Most recently, Dr. Morin worked at Public Relations agency with multiple biotech clients increasing their visibility and reputation in front of stakeholders. At Annovis, Dr. Morin is driving communications efforts on all fronts ensuring the transparency and quality of the company's messaging.

‍

Ms. Liu has over 19 years of experience in design, analysis, and reporting all phases of clinical trials across a broad range of therapeutic areas. She brings deep expertise in statistical methodology, including authoring statistical analysis plans, developing programming specifications, and interpreting complex data to support regulatory submissions. In addition to her technical strengths, Ms. Liu has led high-performing teams, managed large accounts, and driven strategic initiatives with a focus on quality, efficiency, and collaboration.

‍